Organizing Committee


Organizers of the 5th IAASS 2021: scientific curricula & career path.

enzoEnzo Tramontano holds a degree (1990)from the University of Cagliari (Italy), he was Visiting Research Scientist at the Dept. of Pharmacology at Yale University Medical School (CT, USA, 1990-1992 and 1996-1998). He was given two awards granted by the Istituto Superiore di Sanità for “Research in the HIV field: AIDS Project”, for research activities performed in national (1993-1995) and international (1996-1998) institutions. Since 1998 he has worked at the Departments of Experimental Biology (1998-2003), Biomedical Sciences and Technologies (2003-2007), Applied Sciences in Biosystems (2007-2010) and Life and Environmental Sciences (2011-2016) at the University of Cagliari, being appointed as Research Associate (1998), Assistant Professor (2001), Associate Professor (2006) and Full Professor (2015). From 2015 he is also associated to the Institute of Genetic and Biomedical Research of the National Research Council (CNR) in Cagliari. Since 2006 he is head of the Molecular Virology laboratory of the Department of Life and Environmental Sciences of the University of Cagliari. From 2012 to 2015 he has been Vice-Director of the Department of Life and Environmental Sciences, from 2013 is Director of the PhD program in “Life, Environmental and Drug Sciences” and from 2015 he is Dean of the Faculty of Biology and Pharmacy of the University of Cagliari. He is founder member of the European Society of Virology, the International Society for Antiviral Research (for which he is Ambassador for Italy), the Italian Society of Virology and the Italian Society of General Microbiology and Microbial Biotechnologies (for which is currently member of the Executive Council).

Reuben Harris is a Professor of Biochemistry, Molecular Biology and Biophysics, the Associate Director of the Institute for Molecular Virology, and a Member of the Masonic Cancer Center at the University of Minnesota. He received his B.S. (1993) and Ph.D. (1997) degrees from the University of Alberta and performed postdoctoral work at Baylor College of Medicine (1997-1998), Yale University (1998), and Cambridge University (1998-2003). He joined the University of Minnesota as an Assistant Professor in 2003 and was promoted to Associate Professor with Tenure in 2008 and to Full Professor in 2013. Dr. Harris has received numerous grants and awards, including a Searle Scholarship, membership to the American Academy of Microbiology, and a Distinguished McKnight University Professorship. In 2015, he was also appointed as a Howard Hughes Medical Institute Investigator. Dr. Harris is an Associate Editor for Science Advances and an Editorial Board Member for Journal of Biological ChemistryJournal of Virology, and Cancer Research. He has published over 160 manuscripts, contributed to 13 patent applications, and co-founded a cancer therapeutics company. Dr. Harris’s scientific passion is elucidating mechanisms of mutation and establishing relevance to human biology and disease. As a doctoral student, he discovered a novel recombination-dependent mutation process operative in stationary-phase bacteria with implications for antibiotic resistance and microbial evolution. As a postdoctoral fellow, he helped solve an immunology Rosetta stone by discovering the DNA cytosine deaminase activity of AID and proposing a DNA deamination model for antibody gene diversification. Also as a postdoctoral fellow, he discovered the DNA cytosine deaminase activity of several APOBEC family members and, during the transition to faculty, elucidated a new mechanism of antiviral immunity by demonstrating APOBEC3G-catalyzed retroviral cDNA hypermutation. As a Principal Investigator, Dr. Harris has become known for his work on APOBEC enzymes in antiviral immunity, including discovering multiple APOBEC3s in HIV-1 restriction, demonstrating the mechanism by which HIV-1 Vif degrades APOBEC3 proteins, and elucidating the first structures of APOBEC-ssDNA and APOBEC-RNA complexes. This body of work has shed light on fundamental mechanisms of antiviral immunity and yielded new strategies for drug development. In recent years, Dr. Harris’s virology studies have also enabled a major breakthrough in cancer research. His group found that APOBEC3B and APOBEC3H are responsible for a large proportion of mutations in breast, head/neck, lung, bladder, cervical, and other cancers. Independent work has confirmed these results and indicated that “APOBEC mutagenesis” far exceeds most other sources of mutations in cancer, including those attributable to smoking and UV rays. This breakthrough has created new opportunities for cancer diagnosis, prognosis, and treatment by targeting tumor evolvability.

Elias Maccioni (1966) holds a degree from the University of Cagliari, Italy, (1990) and was appointed Assistant Professor of medicinal chemistry in 1992. In 1993 to 1994 he was Visiting Researcher at the Department of Chemistry of the University of Bangor, North Wales. In 2005 he was appointed Associate Professor of Medicinal Chemistry at the Faculty of Pharmacy of the University of Cagliari. He now leads a research group of Drug Discovery at the Department of Life and Environmental Sciences of the University of Cagliari. He is member of the Italian society of Medicinal Chemistry and coordinates the PhD school of Medicinal Chemistry at the University of Cagliari. Moreover he is coordinator of the Paul Ehrlich Network of European Medicinal Chemistry PhD for the University of Cagliari. His research is mainly directed towards the design and synthesis of HIV 1 reverse transcriptase and human monoamine oxidase inhibitors.

Cristina Parolin received the Bachelor Degree in Biology (1988), the PhD in Basic and Applied Microbiology (1995) from the University of Padova and the Specialty diploma in Microbiology and Virology (1998) from the University of Genova. She was “Research fellow” and Research Associate (1991-1997) at the Dana-Farber Cancer Institute, Harvard Medical School, Boston. She was appointed as Research Associate (1998) and Assistant Professor (2001) at the University of Padova, where she is now Professor in Microbiology since 2006 (Department of Molecular Medicine). Member of the Italian Society of Virology (Board 2008-); Italian Society of General Microbiology and Microbial Biotechnologies (Board) (2003-2006); International Committee for Taxonomy of Viruses (ICTV) (Italian representative) (from 2004); European Society for Virology (from 2009). Author of publications on national and international “peer-reviewed” journals. Major research interests are: studies on the mechanism of action of antiviral compounds; development of retroviral vectors for transgene expression (1995: “European Gene Therapy Award – Fondazione Baschirotto”; 1997: LINUS PAULING AWARD; patent for heterologous gene expression by means of an HIV-1 vector “Novel expression vectors and method of use”, PCT/US96/16531); lentivirus biology (life cycle, HIV/herpesviruses interactions and role on AIDS pathogenesis); interactions between viral and cellular proteins in order to identify potential targets for antiviral approaches.

Angela Corona graduated in Pharmaceutical Chemistry at the University of Cagliari in 2010 and hearned in 2014 the Ph.D. in Biology and Biochemistry. She was Guest Researcher in 2011/2012 at the Drug Resistance Program, Center for Excellence in HIV / AIDS and Cancer Virology, Center for Cancer Research at the National Cancer Institute, MD, USA and in 2013 at the Laboratoire de biologie et pharmacologie appliquée,Ecole Normale Superieure de Cachan, Paris. Since 2015 she has been assigned research at the Molecular Virology Laboratory of the Department of Life and Environmental Sciences at the University of Cagliari. In 2017 he was Research Fellow at the IrsiCaixa AIDS Research Institute, Hospital Germans Trias and Pujol, Barcelona. Her research activity focuses on the development and characterization of the mechanism of action of antiviral activity molecules with innovative targets, in particular the ribonucleasic function associated with reverse transcriptase of HIV-1 and VP35 protein of Ebola virus. Member since 2011 of the Italian Society for Virology, since 2014 of the International Society for Antiviral Research and of the Italian Society of Microbiology and Microbial Biotechnologies, since 2016 is a member of the American Society for Microbiology. Dr. Corona is the author and co-author of 56 scientific publications and works as a referee for numerous international journals. For his research activities she was awarded the “Cecilia Cioffrese- Malattie Virali 2016” prize by the Carlo Erba Foundation and in 2017 the Chu Family Foundation (CFF) Women Scientists Award.

Le griceStuart Le Grice received his Ph.D. from the Department of Biochemistry, University of Manchester, UK, in 1976, where he studied the mechanisms of R-factor-mediated multidrug resistance in Escherichia coli. After postdoctoral training in the United Kingdom, Germany, and the United States, he was appointed Senior Scientist in the Central Research Units of Hoffmann La Roche, Basel, Switzerland, where he worked from 1984 to 1990 evaluating HIV-1 and HIV-2 enzymes as therapeutic targets. In 1990, he joined the faculty in the Division of Infectious Diseases, Department of Medicine, Case Western Reserve University (CWRU), Cleveland, OH. Initially recruited as an Associate Professor of Medicine, he was awarded tenure in 1992, and in 1995 was promoted to Professor of Medicine, Biochemistry, and Oncology. From 1994 to 1999, he served as Director of the NIH-funded CWRU Center for AIDS Research. Dr. Le Grice joined the National Cancer Institute in 1999 as Chief of the Resistance Mechanisms Laboratory in the HIV Drug Resistance Program, Center for Cancer Research (CCR), and in 2005 was appointed to the Senior Biomedical Research Service. In 2006, he was appointed Head of the Center of Excellence in HIV/AIDS & Cancer Virology, CCR. He is now head of the Basic Research Laboratory at the Center for Cancer Research of the National Cancer Institute. He is a member of the CCR HIV and Cancer Virology faculty, Chemistry and Biology faculty, and the Steering Committee of the Molecular Targets Discovery Program. In addition to serving on the Editorial Board of the Journal of Biological Chemistry, Dr. Le Grice has been an ad hoc (1990-1999) and permanent Study Section member of NIH AIDS review panels (2000-2004), as well as an ad hoc reviewer for several international funding agencies.


credits Università degli Studi di Cagliari
C.F.: 80019600925 - P.I.: 00443370929
note legali | privacy